Incyte receives EU boost for Opzelura, shares near fresh 52-week high
26.06.2026 - 15:44:41 | ad-hoc-news.de
By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 15:44.
Incyte (US45337C1027) today announced a positive CHMP opinion for Opzelura cream in adults with moderate atopic dermatitis, while its shares continue to trade on Nasdaq after a robust 60 percent one-year gain as tracked by recent market data.Business Wire press release on the CHMP opinion
Opzelura moves closer to EU approval
According to a Business Wire release dated June 26, 2026, the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of Opzelura, a ruxolitinib cream, for moderate atopic dermatitis in adult patients who are not adequately controlled with topical corticosteroids or calcineurin inhibitors.CHMP opinion announcement The company reports that this opinion is a key step toward formal marketing authorization in the European Union, where dermatology peers such as Sanofi and L'Oréal’s dermatology units already compete in the atopic dermatitis segment.MarketScreener summary of recent Incyte news and analyst moves
The CHMP’s positive stance follows earlier regulatory momentum for Opzelura, including a settlement with the U.S. Centers for Medicare & Medicaid Services on Medicaid rebate treatment that is expected to deliver a one-time non-cash benefit of roughly 246 million dollars in the second quarter of 2026, according to Investing.com.Investing.com report on Incyte’s stock and Opzelura settlement This regulatory and financial backdrop forms part of the narrative supporting Incyte’s dermatology franchise alongside larger biopharma peers such as AbbVie and Eli Lilly that also target inflammatory skin diseases.
Analysts lift price targets as shares advance
On the equity side, Nasdaq-listed Incyte shares recently hit a 52-week high of 112.32 dollars and now trade around 114 dollars with a market capitalization of roughly 22 billion dollars, according to Investing.com’s latest snapshot.Investing.com data on price and market cap The same report notes a one-year price change of about 60.9 percent, a marked outperformance versus many U.S. biotech peers in the mid-cap oncology and immunology space.
Analyst commentary has followed the regulatory developments. UBS recently raised its price target on Incyte to 113 dollars from 103 dollars while maintaining a Neutral rating, citing the Opzelura progress and broader pipeline momentum, as summarized by MarketScreener.UBS price target adjustment Investing.com additionally reports that Truist has lifted its target to 105 dollars with a Hold stance, H.C. Wainwright reiterates a Buy rating with a 140 dollar target, and BMO Capital has upgraded the stock from Underperform to Market Perform with a 94 dollar target, indicating a clear but mixed valuation view across the analyst spectrum.Investing.com recap of analyst calls
Further news and data on the Incyte shares
All recent headlines, price data and regulatory updates on Incyte can be found in the ad-hoc-news topic section and on the company’s own investor relations pages.
The business behind the stock
Incyte generates most of its revenue from oncology and inflammation therapies, with lead product Jakafi for myelofibrosis and polycythemia vera forming a core cash engine in the U.S. market alongside newer launches such as Opzelura in dermatology.Zacks review of Incyte’s Q1 2026 metrics Zacks reports that Incyte posted first-quarter 2026 revenue of 1.27 billion dollars, up 20.9 percent year-on-year, with earnings per share of 1.81 dollars versus 1.16 dollars a year earlier, both above consensus estimates.
Beyond its marketed portfolio, the company is investing in pipeline assets such as tafasitamab combinations in lymphoma and INCA033989 in myeloproliferative neoplasms, with updated Phase 1 and Phase 3 data presented at recent hematology congresses according to MarketScreener’s aggregation of Incyte press releases.MarketScreener summary of tafasitamab trial results A collaboration with Mirum Pharmaceuticals on Zilurgisertib in fibrodysplasia ossificans progressiva also adds a rare-disease angle, with Intellectia.AI citing meaningful reductions in heterotopic ossification lesion volume in a recent study update.Intellectia.AI note on Mirum and Incyte FOP study
Where the stock trades today
Incyte shares (US45337C1027) trade on Nasdaq, with recent indications around 110.74 dollars at the close on June 25, 2026, based on TradingKey’s technical data for the INCY ticker.TradingKey technical overview for Incyte
Key data on the Incyte shares
- Company: Incyte Corporation
- ISIN: US45337C1027
- WKN: 896133
- Ticker: INCY
- Trading venue: NASDAQ
- Price (as of 2026-06-25, 16:00): 110.74 USD
- Market cap: 21.98 billion USD (as of 2026-06-25)
- Sector / industry: Pharmaceuticals & Biotechnology
- Index membership: NASDAQ composite
- Next earnings date: not officially scheduled
Disclaimer: This text is for informational purposes only and does not constitute investment advice, an offer, or a recommendation to buy or sell any security. All data cited are based on sources believed to be reliable at the time of writing but may change without notice. Retail investors should conduct their own research or consult a licensed financial advisor before making investment decisions.
